Complex sentence: Brivanib alaninate or BMS-582664 is an investigational, oral, anti-tumorigenic being developed by Bristol-Myers Squibb for the treatment of hepatocellular carcinoma or HCC (also called "malignant hepatoma"), the most common type of liver cancer.
Split into simpler sentences: Brivanib alaninate or BMS-582664 is an investigational, anti-tumorigenic drug intended for oral administration. The drug is being developed by Bristol-Myers Squibb for the treatment of hepatocellular carcinoma or HCC (also called "malignant hepatoma"), the most common type of liver cancer.